TrialsgrambetaRCTs are beautiful

CHARM

2003

Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity — Overall Programme

In 7,601 patients with symptomatic chronic heart failure, candesartan reduced cardiovascular death and heart-failure hospitalisation compared with placebo.

Result

Efficacy: All-cause mortality (overall programme)unadjusted HR 0.91 (95% CI 0.83-1.00) · P = 0.055

Below 1 favours candesartan, above 1 favours placebo.

Event rates
Absolute difference
2 points

The absolute difference is derived from the event rates.

Also reported: Covariate-adjusted HR 0.90, P=0.032); CV death and HF hospitalisations significantly reduced.

Original publication
Subtopic
ARB
Design
Pooled analysis of three double-blind placebo-controlled RCTs
Relevance
Supporting: context rather than must-know.
Source
Pfeffer MA, et al. Lancet. 2003;362(9386):759-766.doi 10.1016/S0140-6736(03)14282-1

Discussion & critique

Overall all-cause mortality endpoint only borderline (significant after adjustment), and the programme pooled distinct HFrEF and HFpEF populations. Established candesartan as an ACEi alternative and add-on in HFrEF.